Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER plus endocrine-resistant breast cancer xenograft models

被引：1
|
作者：
Shomali, Maysoun
Guo, Zhuyan
Cheng, Jane
Sullivan, Amy
El-Ahmad, Youssef
Sun, Fangxian
Sidhu, Sukhvinder
Lee, Joon Sang
Cai, Hui
Pollard, Jack
Debussche, Laurent
Soria, Chris
Bouaboula, Monsif
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P4-02-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-08
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma
    Zuo, Pengcheng
    Li, Yaopeng
    Wang, Tantan
    Lin, Xingyu
    Wu, Zhen
    Zhang, Junting
    Liao, Xuebin
    Zhang, Liwei
    JOURNAL OF NEURO-ONCOLOGY, 2023, 163 (01) : 159 - 171
  • [32] A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma
    Pengcheng Zuo
    Yaopeng Li
    Tantan Wang
    Xingyu Lin
    Zhen Wu
    Junting Zhang
    Xuebin Liao
    Liwei Zhang
    Journal of Neuro-Oncology, 2023, 163 : 159 - 171
  • [33] Patterns of treatment and outcomes in real world elderly patients with metastatic oestrogen receptor positive (ER plus ) breast cancer receiving the CDK4/6 inhibitor Palbociclib and endocrine therapy
    Skrobo, D.
    Prior, L.
    Walshe, J.
    Gullo, G.
    Crown, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S102 - S103
  • [34] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer
    Liu, Renyan
    Pantelidou, Constantia
    Jadhav, Heta
    Shapiro, Geoffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [35] β-catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine-resistant breast cancer cells
    Ham, Ahrong
    Cho, Min Hee
    Won, Hye Sung
    Jo, Jungmin
    Lee, Kyoung Eun
    ONCOLOGY REPORTS, 2022, 48 (01)
  • [36] Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
    Carla L. Alves
    Sidse Ehmsen
    Mikkel G. Terp
    Neil Portman
    Martina Tuttolomondo
    Odd L. Gammelgaard
    Monique F. Hundebøl
    Kamila Kaminska
    Lene E. Johansen
    Martin Bak
    Gabriella Honeth
    Ana Bosch
    Elgene Lim
    Henrik J. Ditzel
    Nature Communications, 12
  • [37] Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
    Herrera-Abreu, M. T.
    Guan, J.
    Khalid, U.
    Ning, J.
    Costa, M. R.
    Chan, J.
    Li, Q.
    Fortin, J-p.
    Wong, W. R.
    Perampalam, P.
    Biton, A.
    Sandoval, W.
    Vijay, J.
    Hafner, M.
    Cutts, R.
    Wilson, G.
    Frankum, J.
    Roumeliotis, T. I.
    Alexander, J.
    Hickman, O.
    Brough, R.
    Haider, S.
    Choudhary, J.
    Lord, C. J.
    Swain, A.
    Metcalfe, C.
    Turner, N. C.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [38] Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
    Sun, Chao-Yue
    Talukder, Milton
    Cao, Di
    Chen, Cun-Wu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] Anti-tumor activity of CDK2 inhibitor BLU-222 in combination with CDK4/6 inhibitors for overcoming resistance in HR positive and triple negative metastatic breast cancers models
    Luo, Linjie
    Wang, Yan
    Bui, Tuyen
    Li, Mi
    Kim, Serena
    Navarro-Yepes, Juliana
    Kettner, Nicole M.
    Tripathy, Debasish
    Hunt, Kelly K.
    Faia, Kerrie
    Keyomarsi, Khandan
    CANCER RESEARCH, 2024, 84 (06)
  • [40] Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
    Kase, Adam M.
    Gleba, Justyna
    Miller, James L.
    Miller, Erin
    Petit, Joachim
    Barrett, Michael T.
    Zhou, Yumei
    Parent, Ephraim E.
    Cai, Hancheng
    Knight, Joshua A.
    Orme, Jacob
    Reynolds, Jordan
    Durham, William F.
    Metz, Thomas M.
    Meurice, Nathalie
    Edenfield, Brandy
    Demirer, Aylin Alasonyalilar
    Bilgili, Ahmet
    Hickman, Peyton G.
    Pawlush, Matthew L.
    Marlow, Laura
    Wickland, Daniel P.
    Tan, Winston
    Copland III, John A.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (06) : 823 - 835
12345